Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose

[1]  F. Saudou,et al.  Pridopidine rescues BDNF/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model , 2022, Neurobiology of Disease.

[2]  B. Darpo,et al.  ECG Evaluation as Part of the Clinical Pharmacology Strategy in the Development of New Drugs: A Review of Current Practices and Opportunities Based on Five Case Studies , 2022, Journal of clinical pharmacology.

[3]  M. Geva,et al.  Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine , 2022, Autophagy.

[4]  A. Johri,et al.  Connection Lost, MAM: Errors in ER–Mitochondria Connections in Neurodegenerative Diseases , 2021, Brain Sciences.

[5]  M. Hayden,et al.  Pridopidine reduces mutant huntingtin‐induced endoplasmic reticulum stress by modulation of the Sigma‐1 receptor , 2021, Journal of neurochemistry.

[6]  M. Hayden,et al.  The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models , 2021, Neurotherapeutics.

[7]  M. Hayden,et al.  Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study , 2020, Journal of Huntington's disease.

[8]  T. Maurice.  Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders , 2020, Expert opinion on drug discovery.

[9]  M. Hayden,et al.  Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor , 2019, Neurobiology of Disease.

[10]  I. Bezprozvanny,et al.  Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases , 2019, Front. Neurosci..

[11]  L. Raymond,et al.  Alterations in synaptic function and plasticity in Huntington disease , 2019, Journal of neurochemistry.

[12]  R. Reilmann,et al.  International Guidelines for the Treatment of Huntington's Disease , 2019, Front. Neurol..

[13]  J. Brotchie,et al.  Pridopidine, a clinic‐ready compound, reduces 3,4‐dihydroxyphenylalanine‐induced dyskinesia in Parkinsonian macaques , 2019, Movement disorders : official journal of the Movement Disorder Society.

[14]  I. Bezprozvanny,et al.  Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor , 2019, Neurobiology of Disease.

[15]  M. Hayden,et al.  Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse , 2018, Molecular Neurodegeneration.

[16]  P. McColgan,et al.  Huntington's disease: a clinical review , 2018, European journal of neurology.

[17]  Georg Ferber,et al.  Correction to: Scientific white paper on concentration-QTc modeling , 2018, Journal of Pharmacokinetics and Pharmacodynamics.

[18]  Georg Ferber,et al.  Scientific white paper on concentration-QTc modeling , 2017, Journal of Pharmacokinetics and Pharmacodynamics.

[19]  T. Su,et al.  Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases , 2017, Journal of Biomedical Science.

[20]  I. Bezprozvanny,et al.  The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease , 2017, Neurobiology of Disease.

[21]  M. Hayden,et al.  Pridopidine activates neuroprotective pathways impaired in Huntington Disease , 2016, Human molecular genetics.

[22]  M. Strong,et al.  The global prevalence of Huntington's disease: a systematic review and discussion. , 2016, Neurodegenerative disease management.

[23]  Jane S. Paulsen,et al.  Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. , 2016, JAMA.

[24]  M. Hayden,et al.  Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk , 2014, Movement disorders : official journal of the Movement Disorder Society.

[25]  E Ray Dorsey,et al.  Natural history of Huntington disease. , 2013, JAMA neurology.

[26]  Borje Darpo,et al.  Early QT assessment – how can our confidence in the data be improved? , 2013, British journal of clinical pharmacology.

[27]  J. Jankovic,et al.  Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington’s and Other Diseases , 2013, Tremor and other hyperkinetic movements.

[28]  B. Leavitt,et al.  A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[29]  Chris Frost,et al.  Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data , 2013, The Lancet Neurology.

[30]  M. Malik,et al.  Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects. , 2012, American heart journal.

[31]  Chris Frost,et al.  Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data , 2012, The Lancet Neurology.

[32]  R. Barker,et al.  Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial , 2011, The Lancet Neurology.

[33]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[34]  R. Roos,et al.  Huntington's disease: a clinical review , 2010, Orphanet journal of rare diseases.

[35]  Norman Stockbridge,et al.  Concentration‐QT Relationships Play a Key Role in the Evaluation of Proarrhythmic Risk During Regulatory Review , 2008, Journal of clinical pharmacology.

[36]  Teruo Hayashi,et al.  Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival , 2007, Cell.

[37]  Teruo Hayashi,et al.  Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. , 2007, Cell.

[38]  Giuseppe Curigliano,et al.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[39]  Teruo Hayashi,et al.  σ-1 Receptors (σ1 Binding Sites) Form Raft-Like Microdomains and Target Lipid Droplets on the Endoplasmic Reticulum: Roles in Endoplasmic Reticulum Lipid Compartmentalization and Export , 2003, Journal of Pharmacology and Experimental Therapeutics.

[40]  Teruo Hayashi,et al.  Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export. , 2003, The Journal of pharmacology and experimental therapeutics.

[41]  E. Siemers,et al.  Rate of functional decline in Huntington’s disease , 2000, Neurology.

[42]  N. Quinn,et al.  Huntington’s disease and other choreas , 1998, Journal of Neurology.

[43]  Jan Pool,et al.  QTc Prolongation Measured by Standard 12‐Lead Electrocardiography Is an Independent Risk Factor for Sudden Death Due to Cardiac Arrest , 1991, Circulation.